Loading organizations...
Hologic is a medical technology company specializing in the development and commercialization of diagnostic products, medical imaging systems, and surgical solutions primarily for women’s health. The company’s portfolio encompasses advanced technologies for breast health, gynecological health, sexual health, and skeletal health, alongside a range of molecular diagnostics and laboratory technologies designed to enhance early detection and treatment across various conditions. Their integrated platforms deliver precise tools to healthcare professionals globally.
Hologic was founded in 1985 by S. David Ellenbogen and Jay Stein. Their initial vision was to establish a company dedicated to innovation within medical technology, driven by a commitment to developing solutions that positively impact health outcomes. This founding principle guided the company's early efforts to create a singular product and has since expanded to a comprehensive suite of offerings.
The company serves healthcare providers and their patients by equipping them with technologies that enable more accurate diagnoses and effective interventions. Hologic's long-term vision centers on championing women’s health on a global scale. It strives to advance scientific standards and ensure broad access to its innovations, working to dismantle barriers that hinder women from receiving essential care.
Hologic has 1 tracked investment across 1 company. The latest tracked deal is $59.0M Series B in Mercy BioAnalytics in September 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 3, 2025 | Mercy BioAnalytics | $59.0M Series B | Paul Meister, Novalis Lifesciences, ROB Freelen | Avestria Ventures, Brightedge Ventures, Bruker, ISelect Fund, Labcorp, Mindshift Capital, Perceptive Xontogeny Venture Fund, Portfolia |